Organotypic systems in drug metabolism and toxicity: challenges and opportunities
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The frequent failure of high-throughput screening cell-based tools to accurately predict in vivo responses, coupled with limitations of animal models in predicting human safety or drug efficacy, impairs the de-risking process for biotechnology/pharmaceutical companies as they make important decisions to enter human clinical trials. Organotypic systems strive to fill the gap between these screening and in vivo studies and provide a solution. AREAS COVERED: The authors examine the various approaches to recreate physiological response on the bench and trace the evolution of organotypic systems, while discussing intrinsic challenges and opportunities that lie ahead. Furthermore, they cite literature that is the foundation of several biotechnology research companies addressing this issue and discuss major government-funded initiatives to aid the development of these systems in an effort to fill this existing gap. EXPERT OPINION: Decisions from translational systems that bridge basic drug efficacy and toxicity with clinical outcome must be benchmarked against human-relevant endpoints and clinical data for early meaningful pre-clinical decisions. The use of human primary cells coupled with emerging technologies that allow precise control of the culture environment and analysis of meaningful endpoints paves the way for human organotypic systems as a major initiative in de-risking the drug discovery and development process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 4×
“In this review, we cite literature from several biotechnology research companies that are addressing this issue, including Hepregen [10,93], HemoShear [13,14], CellAsics [11], Hurel [8,95], Regenemed [82] and Zyoxel [9,40], and the advantages that these systems offer over standard systems is summarized in Table 1.”
BackgroundInfluentialEfficacy of Oral N-Acetylcysteine in the Treatment of Acetaminophen Overdose
Smilkstein, M. J., Knapp, G. L., Kulig, K. W., & Rumack, B. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192401 · Cited by 1,102
Bhatia, S. N., Balis, U. J., Yarmush, M. L., & Toner, M. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.14.1883 · Cited by 890 · cited 1×
“Surfaces with similarly engineered substrates have been shown to enhance liver-specific function while increasing long-term viability for toxicological studies [10,85].”
BackgroundWilkening, S., Stahl, F., & Bader, A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.8.1035 · Cited by 794 · cited 1×
“However, constraints such as cost and lack of access to primary cells could influence the choice of available immortalized cell lines such as HepG2 [100,101] and HepaRG [102] in spite of their drawbacks such as incomplete or low expression of the different metabolic genes and instability over multiple passages.”
BackgroundDeLeve, L. D., Wang, X., & Guo, Y. (2008) · Hepatology · doi:10.1002/hep.22351 · Cited by 408 · cited 1×
“[73] have demonstrated that a co-culture with freshly isolated SECs markedly decreased HSC activation after 3 days in culture, but co-culture with SECs that have lost their differentiated state had no effect.”
BackgroundChang, T. T., & Hughes-Fulford, M. (2009) · Tissue Engineering Part A · doi:10.1089/ten.tea.2007.0434 · Cited by 311
LeCluyse, E. L., Audus, K. L., & Hochman, J. H. (1994) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1994.266.6.c1764 · Cited by 266
Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor
Powers, M. J., Janigian, D. M., Wack, K. E., Baker, C. S., Stolz, D. B., & Griffith, L. G. (2002) · Tissue Engineering · doi:10.1089/107632702760184745 · Cited by 234 · cited 2×
“The technology consists of scaffolds with channels housing capillary bed-sized liver tissue units that are continuously perfused with culture medium [12,39].”
BackgroundKidambi, S., Yarmush, R. S., Novik, E., Chao, P., Yarmush, M. L., & Nahmias, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906820106 · Cited by 213
Effect of Collagen Gel Configuration on the Cytoskeleton in Cultured Rat Hepatocytes
Ezzell, R. M., Toner, M., Hendricks, K., Dunn, J. C. Y., Tompkins, R. G., & Yarmush, M. L. (1993) · Experimental Cell Research · doi:10.1006/excr.1993.1266 · Cited by 98
Cited by
3D cell culture systems modeling tumor growth determinants in cancer target discovery
Thoma, C. R., Zimmermann, M., Agarkova, I., Kelm, J. M., & Krek, W. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.03.001 · Cited by 478
Microengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116
“Since then, as illustrated with examples above, several attempts have been made to mimic one or more of these cues in vitro depending on the application at hand and throughput desired.(11,12,94) As a result of such research, the use of in vitro liver models in drug development and other life science applications has s…”
BackgroundMethodHemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro
Dash, A., Simmers, M. B., Deering, T. G., Berry, D. J., Feaver, R. E., Hastings, N. E., Pruett, T. L., LeCluyse, E. L., Blackman, B. R., & Wamhoff, B. R. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00331.2012 · Cited by 108
Self-citationMicrofluidic system for modelling 3D tumour invasion into surrounding stroma and drug screening
Du, Z., Mi, S., Yi, X., Xu, Y., & Sun, W. (2018) · Biofabrication · doi:10.1088/1758-5090/aac70c · Cited by 42
Terelius, Y., Figler, R. A., Marukian, S., Collado, M. S., Lawson, M. J., Mackey, A. J., Manka, D., Qualls, C. W., Blackman, B. R., Wamhoff, B. R., et al. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.11.023 · Cited by 33
Self-citation
Metadata
- Authors
- Dash, A., Blackman, B. R., & Wamhoff, B. R.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2012-05-26
- Volume
- 8
- Issue
- 8
- Pages
- 999-1014
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2131068275
- Cited by
- 21
- References
- 10
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Organotypic systems in drug metabolism and toxicity: challenges and opportunities. https://app.cochat.ai/papers/10.1517/17425255.2012.693161
- The paper
- Dash, A., Blackman, B. R., & Wamhoff, B. R. (2012). Organotypic systems in drug metabolism and toxicity: challenges and opportunities. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2012.693161
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.